KEYNOTE-679 / ECHO-302: This Phase III trial is evaluating an intravenous immunotherapy drug (Pembrolizumab) and three oral drugs (Epacadostat, Sunitinib and Pazopanib) for the treatment of locally advanced or metastatic renal cell carcinomaA Randomized, Open-Label, Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care (Sunitinib or Pazopanib) as First-Line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC)

Exclusion

• Use of protocol-defined prior/concomitant therapy.
• Currently receiving or has received an investigational treatment as part of a study of an investigational agent or has used an investigational device within 4 weeks before randomization.
• History of severe hypersensitivity reaction to study treatments or their excipients.
• Active autoimmune disease that has required systemic treatment in past 2 years.
• Known additional malignancy that has progressed or has required active treatment in the last 3 years.
• Known active central nervous system metastases and/or carcinomatous meningitis.
• History of (noninfectious) pneumonitis that required steroids or current pneumonitis.
• History or presence of an abnormal electrocardiogram that, in the investigator's opinion, is clinically meaningful.
• Significant cardiac event within 12 months before Cycle 1 Day 1.